OUS

Oslo, Norway
Oslo, Norway

Time filter

Source Type

-- The Swedish punk rock crew called Our Untold Story have released their latest official video, "Calm Seas Don't Make Good Sailors." Like the rest of the OUS catalog, the video has been proudly published on the Cuprite Productions independent record label without the involvement of the corporate music industry. Driving, upbeat, minimalist and thrumming with energy, "Calm Seas Don't Make Good Sailors" is the most significant official video from Our Untold Story to date.Our Untold Story's Xander Turian has cited as main artistic influences such legends as Iggy & the Stooges, the Hives, Green Day, and Blink 182, all of which groups boast similarities with Stockholm's Our Untold Story. Turian has also mentioned a deep love for bands like the Rolling Stones, Dire Straits, the Doors and the Beatles, however, and this classic rock vein tempers OUS's minimalist, pop-punk sound into something that is palatable to a surprisingly broad audience across cultures and ages.In fact, this seemingly natural knack for rocking across boundaries is a central theme of their new "Calm Seas..." video. It speaks to everyone, woman and man, young and old alike."The message I want to portray, is that no matter which path you end up choosing, choose the one that makes you happy, not the one you think is expected of you," writes Turian. "'Calm Seas Don't Make Good Sailors' means that it is the rough times that truly make you who you are, and make you all the stronger for it."The video directed by Johannes S. Karpe portrays Xander Turian as an archetype of humanity growing up with rock 'n' roll music from toddler to family man. His youth is played by his real-life siblings, with a cameo of his actual father playing Turian at middle age with children of his own."As the song progresses,"says Turian, "we see the boy in his teenage years, clearly putting music to one side as he focuses on girls, only to find himself in a rut surrounded by trash and dusty instruments, trying to write a new song. After the realities of life have taken their toll and our protagonist reluctantly puts on a suit and tie, we see him in the future, settling down with his kids to watch the same band playing on the computer."The kids are all played by my younger siblings and the adult "future" me is played by my father."Calm Seas Don't Make Good Sailors" is the accompanying B-side to last year's "Go for Broke," which was also released by Our Untold Story with an official music video. Both are expected to feature on the upcoming Our Untold Story album, "My Dreams, My Rules," which is rumored to have a 2018 drop date.The "Calm Seas Don't Make Good Sailors" official video by Our Untold Story is available online worldwide for viewing now. Get in early.-S. McCauleyLead Press Release Writerwww.MondoTunes.com


Teleradiology Services Market is Expected to Reach a CAGR of 21.0% During 2016– 2026 Future Market Insights has announced the addition of the “Teleradiology Services Market: Global Industry Analysis and Opportunity Assessment, 2016-2026" report to their offering. Valley Cottage, NY, May 14, 2017 --( The global teleradiology services market is anticipated to project exponential growth over the next 10 years owing to increasing incidences of chronic diseases such as cancer, tumours, and orthopaedic diseases; increasing geriatric population; and excessive hospitalisations and increasing admittance in ambulatory surgical centres and clinics. Increasing consumer awareness regarding teleradiology and easy accessibility to the technology is another key factor likely to drive the global demand for teleradiology services. However, high cost of technology and services, image transmission issues, dearth of trained radiologists and technicians, and a low awareness in emerging economies is likely to pose major challenges for the growth of the global teleradiology services market. Ongoing trends for teleradiology services driving the global market include service offerings with the latest IT infrastructure including artificial intelligence and algorithms, cloud with low maintenance, and image backup storage. Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2100 Segmentation highlights The global teleradiology services market is segmented on the basis of Process Type (Certified Reporting Services Process, Preliminary Reporting); Service Type (Emergency Nighthawk, Day Time Coverage, Subspecialty Reading, Second Opinion, Clinical Trails); Modality (X-Ray Scans, Computerised Tomography (CT) Scans, MRI Scans, Ultrasound Scans, Nuclear Scans, Cardiac Echo, Mammography, Electromammography); and End User (Hospital Pharmacies, Clinics, Ambulatory Surgical Centres, Radiology Centres). Certified Reporting Services Process segment is estimated to account for 62.9% revenue share of the global teleradiology services market by 2016 end. Emergency Nighthawk service type segment accounted for 31.6% value share in 2015 and is anticipated to dominate the global teleradiology services market throughout the forecast period. Computerised Tomography (CT) Scans modality segment is anticipated to register a CAGR of 23.6% between 2016 and 2026. Hospital Pharmacies end user segment is estimated to account for 39.9% revenue share of the global teleradiology services market by 2016 end. Regional market projections The global teleradiology services market is segmented on the basis of region into U.S. and OUS (International) (Latin America, EU5, Rest of Europe, Japan, Asia Pacific Excluding Japan, Rest of the World). The U.S. regional market dominated the global teleradiology services market in revenue terms in 2015 and is projected to account for 41.2% market value share by 2026 end. The EU5 region is expected to be the second most lucrative segment in the global teleradiology services market with a market attractiveness index of 1.3 during the forecast period. Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-2100 Vendor insights The report profiles some of the leading players operating in the global teleradiology services market. Top companies featured in the report include Teleradiology Solutions, Argus Radiology, SRL Diagnostics, USARAD Holdings Inc., Vital Radiology Services, Teleradiology Providers, Telemedicine Clinic, TeleDiagnosys Services Pvt. Ltd, Imaging Advantage, Foundation Radiology Group, Direct Radiology, Imaging On Call LLC, ONRAD Inc., Rays (Envision Healthcare Company), StatRad LLC, ARIS Radiology, NightShift Radiology, Mednax Inc., Alta Vista TeleRadiology, and Quality Nighthawk. These established players are focussed on strategic moves such as new product launches, increasing their distribution channels, and getting into partnerships and agreements with hospitals and specialty clinics to increase the brand awareness of their product. Valley Cottage, NY, May 14, 2017 --( PR.com )-- Future Market Insights delivers key insights on the global teleradiology services market in a new publication titled “Teleradiology Services Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” Teleradiology is the practice of interpretation and analysis of medical images by a radiologist who is not present at the site where the images are generated. This service is utilised by hospitals, emergency care centres, telemedicine companies, and other clinics. Teleradiology services enable radiologists to use online services in order to improve patient care and treatment without the need to be physically present on site. In terms of revenue, the global teleradiology services market is projected to register a healthy CAGR of 21.0% over the forecast period (2016 – 2026) and increase 6.7x in terms of revenue between 2016 and 2026.The global teleradiology services market is anticipated to project exponential growth over the next 10 years owing to increasing incidences of chronic diseases such as cancer, tumours, and orthopaedic diseases; increasing geriatric population; and excessive hospitalisations and increasing admittance in ambulatory surgical centres and clinics. Increasing consumer awareness regarding teleradiology and easy accessibility to the technology is another key factor likely to drive the global demand for teleradiology services. However, high cost of technology and services, image transmission issues, dearth of trained radiologists and technicians, and a low awareness in emerging economies is likely to pose major challenges for the growth of the global teleradiology services market. Ongoing trends for teleradiology services driving the global market include service offerings with the latest IT infrastructure including artificial intelligence and algorithms, cloud with low maintenance, and image backup storage.Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2100Segmentation highlightsThe global teleradiology services market is segmented on the basis of Process Type (Certified Reporting Services Process, Preliminary Reporting); Service Type (Emergency Nighthawk, Day Time Coverage, Subspecialty Reading, Second Opinion, Clinical Trails); Modality (X-Ray Scans, Computerised Tomography (CT) Scans, MRI Scans, Ultrasound Scans, Nuclear Scans, Cardiac Echo, Mammography, Electromammography); and End User (Hospital Pharmacies, Clinics, Ambulatory Surgical Centres, Radiology Centres).Certified Reporting Services Process segment is estimated to account for 62.9% revenue share of the global teleradiology services market by 2016 end.Emergency Nighthawk service type segment accounted for 31.6% value share in 2015 and is anticipated to dominate the global teleradiology services market throughout the forecast period.Computerised Tomography (CT) Scans modality segment is anticipated to register a CAGR of 23.6% between 2016 and 2026.Hospital Pharmacies end user segment is estimated to account for 39.9% revenue share of the global teleradiology services market by 2016 end.Regional market projectionsThe global teleradiology services market is segmented on the basis of region into U.S. and OUS (International) (Latin America, EU5, Rest of Europe, Japan, Asia Pacific Excluding Japan, Rest of the World). The U.S. regional market dominated the global teleradiology services market in revenue terms in 2015 and is projected to account for 41.2% market value share by 2026 end. The EU5 region is expected to be the second most lucrative segment in the global teleradiology services market with a market attractiveness index of 1.3 during the forecast period.Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-2100Vendor insightsThe report profiles some of the leading players operating in the global teleradiology services market. Top companies featured in the report include Teleradiology Solutions, Argus Radiology, SRL Diagnostics, USARAD Holdings Inc., Vital Radiology Services, Teleradiology Providers, Telemedicine Clinic, TeleDiagnosys Services Pvt. Ltd, Imaging Advantage, Foundation Radiology Group, Direct Radiology, Imaging On Call LLC, ONRAD Inc., Rays (Envision Healthcare Company), StatRad LLC, ARIS Radiology, NightShift Radiology, Mednax Inc., Alta Vista TeleRadiology, and Quality Nighthawk. These established players are focussed on strategic moves such as new product launches, increasing their distribution channels, and getting into partnerships and agreements with hospitals and specialty clinics to increase the brand awareness of their product. Click here to view the list of recent Press Releases from Future Market Insights


— Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Side vision may begin to decrease followed by central vision resulting in blindness, if not treated. Complete report on Glaucoma industry spread across 70 pages with providing 4 company Profiles, 3 tables and 41 charts is now available at http://www.marketreportsonline.com/591783.html. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent. Though, glaucoma cannot be cured completely but the disease progression can be controlled with the help of available treatments. There are three types of modalities available for treatment of glaucoma: Drugs, Laser and Invasive Surgery. Further, based upon the approaches employed for the medication, it can be segmented into two parts: PGA Medication and Non-PGA Medication. The PGA approach reduces IOP with the help of prostaglandin (PGA). The non-PGA medication can be further divided into four sub segments: Beta blockers, Alpha blockers, Carbonic anhydrase inhibitors (CAIs) and Combination Products. Several factors such as rising prevalence of diabetes, growing geriatric population and rising health care expenditure along with increasing disposable income and growing obese population will drive the glaucoma market growth in the next few years. Development of new drugs & devices and drug therapy focused upon IOP are the few notable market trends. However, high cost of treatment, severe side effects and hasty drug approval processes act as a major roadblock for the market growth. The report “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on the US and OUS treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Novartis AG, Merck & Co., Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global glaucoma market along with the study of the US market. Purchase a copy of this “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=591783. New Glaucoma Drugs and Therapy Devices in Pipeline (2016) Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison (2016) Major Product Developments by Pfizer Inc. (Since November 1, 2016) Types of Glaucoma Treatments Available for Glaucoma Glaucoma Pharmaceutical Market by Segment Global Glaucoma Market Forecast by Value (2016-2021) Global Glaucoma Market by Segments (2016) Global Glaucoma Drugs Market Forecast by Value (2016-2021) Global Glaucoma Market by Drug Class (2016) Global Glaucoma Drugs Market by Region (2016) Global Glaucoma Patient Volume Forecast (2016-2021) The US Glaucoma Drugs Market Forecast by Value (2016-2021) The US Glaucoma Patient Volume Forecast (2016-2021) The US Open Angle Glaucoma Patient Volume Forecast (2016-2021) The US Glaucoma Prescription Volume Forecast (2016-2021) The US Glaucoma Drug Market by Type (2016) The US Glaucoma First Line Drugs Market Forecast by Value (2016-2021) The US Glaucoma First Line Drugs Prescription Volume Forecast (2016-2021) The US Glaucoma Second Line Drugs Market Forecast by Value (2016-2021) The US Glaucoma Second Line Drugs Prescription Volume Forecast (2016-2021) Explore more pharmaceuticals market research as well as other newly published reports by Koncept Analytics at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html. For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=591783


The report "Global Glaucoma Market analyzes the development of this market, with focus on the US and OUS treatment market. -- Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Side vision may begin to decrease followed by central vision resulting in blindness, if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent.Though, glaucoma cannot be cured completely but the disease progression can be controlled with the help of available treatments. There are three types of modalities available for treatment of glaucoma: Drugs, Laser and Invasive Surgery. Further, based upon the approaches employed for the medication, it can be segmented into two parts: PGA Medication and Non-PGA Medication. The PGA approach reduces IOP with the help of prostaglandin (PGA). The non-PGA medication can be further divided into four sub segments: Beta blockers, Alpha blockers, Carbonic anhydrase inhibitors (CAIs) and Combination Products.The global healthcare expenditure is indicative of expenditure on medical infrastructure and facilities such as medical cover and reimbursement. The cost of glaucoma therapy is substantial and perhaps even higher in terms of efforts and quality of life. Better medical facilities and efforts of government to either subsidize or reimburse the cost of therapy will eventually help in patients' adherence to therapy. The resulting higher adoption rate and continuation of drugs therapy will eventually lead to higher market penetration. Thus, rising healthcare expenditure is a crucial growth driver for the market.The report "Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)" analyzes the development of this market, with focus on the US and OUS treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Novartis AG, Merck & Co., Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global glaucoma market along with the study of the US market.Types of GlaucomaTreatments Available for GlaucomaGlaucoma Pharmaceutical Market by SegmentGlobal Glaucoma Market Forecast by Value (2016-2021)Global Glaucoma Market by Segments (2016)Global Glaucoma Drugs Market Forecast by Value (2016-2021)Global Glaucoma Market by Drug Class (2016)Global Glaucoma Drugs Market by Region (2016)Global Glaucoma Patient Volume Forecast (2016-2021)The US Glaucoma Drugs Market Forecast by Value (2016-2021)The US Glaucoma Patient Volume Forecast (2016-2021)The US Open Angle Glaucoma Patient Volume Forecast (2016-2021)The US Glaucoma Prescription Volume Forecast (2016-2021)The US Glaucoma Drug Market by Type (2016)The US Glaucoma First Line Drugs Market Forecast by Value (2016-2021)The US Glaucoma First Line Drugs Prescription Volume Forecast (2016-2021)The US Glaucoma Second Line Drugs Market Forecast by Value (2016-2021)The US Glaucoma Second Line Drugs Prescription Volume Forecast (2016-2021)The US MIGS Procedure Volume Forecast (2016-2021)OUS Glaucoma Drugs Market Forecast by Value (2016-2021)Global Type 2 Diabetes Patients Population Forecast (2016-2021)Global Population Older than 60 years (2012-2016)Global Per Capita Healthcare Expenditure (2012-2016)Global GDP per Capita (2012-2016)Global Obese Population (2012-2016)Drug Approval ProcessThe US Glaucoma First Line Drugs Market Share by Company (2016/2021)The US Glaucoma Second Line Drugs Market Share by Company (2016/2021)The US MIGS Market Share by Company (2016/2021)Pfizer Inc. Revenue by Segment (2016)Pfizer Inc.'s Revenue and Net Income (2012-2016)Pfizer Inc. R&D Expenses (2015-2016)Novartis AG Net Sales by Segment (2016)Novartis AG Net Sales and Net Income (2012-2016)Novartis AG R&D Expenditure (2014-2016)Merck & Co., Inc. Sales by Segment (2016)Merck & Co., Inc.'s Sales and Net Income (2012-2016)Merck & Co., Inc.'s R&D Expenditure (2014-2016)Allergan Plc. Net Revenue by Segment (2016)Allergan Plc. Net Revenue and Net Income (2012-2016)Allergan Plc. R&D Expenditure (2014-2016)New Glaucoma Drugs and Therapy Devices in Pipeline (2016)Global Glaucoma Market- Key Companies Revenue & Market Cap Comparison (2016)Major Product Developments by Pfizer Inc. (Since November 1, 2016)For more Information:Koncept AnalyticsVikas Gupta(Business Development Manager)FFCS-36, Ansal PlazaVaishali, GhaziabadU.P - 201010Tele: +91-120-4130959Mobile: +91-9871694789Mail ID – vikas@konceptanalytics.com


News Article | May 8, 2017
Site: www.prnewswire.co.uk

The two-year pivotal study will involve US and OUS centers, with the aim of demonstrating the Agili-C™ implant's superiority over the surgical standard of care. The investment was led by aMoon, together with CartiHeal's existing investors: Johnson & Johnson Innovation (JJDC Inc.), Peregrine Ventures and Elron, who has been consistently supporting and investing in CartiHeal over the years. "CartiHeal delivers hope to those who suffer daily from degenerative and non-degenerative joint conditions, regenerating both bone and cartilage with its Agili-C single-step implantation procedure," says Dr. Yair Schindel, Managing Partner at aMoon. "We are excited to take part in this promising endeavor, already showing remarkable results, and join the highly capable management team and strong investors, in bringing this technology to a growing population of patients globally." "This latest investment round is yet another testament to our investors' confidence in our technology," says Nir Altschuler, CartiHeal's founder and CEO. "We believe the implant can greatly benefit patients suffering from a variety of cartilage lesions, who wish to return to a painless and active lifestyle, and who currently don't have good alternatives." CartiHeal's cell-free, off-the-shelf implant for use in cartilage and osteochondral defects was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 250 patients with cartilage lesions in the knee, ankle, and great toe. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, as per its CE Mark, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. Results of these prior investigations demonstrated the potential for cartilage regeneration and the remodeling of underlying subchondral bone, along with pain and symptom relief. CartiHeal, a privately-held medical device company headquartered in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. The company's flagship product, Agili-C™, is CE marked and has been recently approved by the FDA for an Investigational Device Exemption (IDE) clinical trial toward a PMA application. For more information, please contact: Caty Pearl Catyp@pearlcom.co.il +972-9-8810400


CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application. The 2 year-long pivotal study will involve a minimum of 250 patients in US and OUS centers. The study is aimed to show superiority of the Agili-C™ implant over surgical standard of care, i.e. microfracture and debridement, in the treatment of cartilage/osteochondral defects in both osteoarthritic knees and in knees without degenerative changes, making it the first approved study of such broad indications using a single implant. The study is designed as a prospective, multicenter, open-label, randomized and controlled trial, involving up to 3 lesions in the same joint and with a total treatable area of 1-7cm2. Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. Results of these prior investigations demonstrated the potential for cartilage regeneration and remodeling of the underlying subchondral bone, along with pain and symptom relief. "Pivotal studies performed to date were always focused on small, focal and isolated cartilage lesions in a narrowly defined patient group, which does not represent most of the 'real-life' cases," explains Dr. Ken Zaslav, President of the International Cartilage Repair Society (ICRS) and a member of CartiHeal's Clinical Advisory Board. "Based on the robust clinical data of the Agili-C™ implant, FDA has allowed for the first time, treatment indications ranging from single focal defects to multiple defects in osteoarthritis of the knee, which is what us surgeons see on a daily basis. Moreover, this exciting study will compare two control modes in a single arm: microfracture for the treatment of focal lesions and debridement for patients with osteoarthritis." "Over the last few years we've conducted a series of clinical studies in leading centers to learn which kind of patients can benefit from the Agili-C™ implant," says Nir Altschuler, CartiHeal's founder and CEO.  "Together with our Clinical Advisory Board we designed a study that targets a large patient population who can potentially benefit from this implant. We are very pleased that FDA approved our study design, and believe that the Agili-C™ implant will prove to be an ideal treatment for a variety of cartilage lesions in patients who wish to return to a painless and active lifestyle, and currently don't have good alternatives." CartiHeal, a privately-held medical device company headquartered in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. Backed by extensive pre-clinical and clinical data, its flagship product Agili-C™, an aragonite-based biodegradable scaffold, has been shown to promote restoration of hyaline cartilage and remodeling of its underlying subchondral bone through a natural process, without the use of cells or growth factors. Clinical results in the knee, ankle and big toe demonstrated the potential of significant improvement in pain reduction, as well as reduction in related symptoms - through a simple, single-step implantation procedure. In the United States, the Agili-C is an investigational device that is limited to use in the IDE study.  It is not available for sale.


CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application. The 2 year-long pivotal study will involve a minimum of 250 patients in US and OUS centers. The study is aimed to show superiority of the Agili-C™ implant over surgical standard of care, i.e. microfracture and debridement, in the treatment of cartilage/osteochondral defects in both osteoarthritic knees and in knees without degenerative changes, making it the first approved study of such broad indications using a single implant. The study is designed as a prospective, multicenter, open-label, randomized and controlled trial, involving up to 3 lesions in the same joint and with a total treatable area of 1-7cm2. Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. Results of these prior investigations demonstrated the potential for cartilage regeneration and remodeling of the underlying subchondral bone, along with pain and symptom relief. "Pivotal studies performed to date were always focused on small, focal and isolated cartilage lesions in a narrowly defined patient group, which does not represent most of the 'real-life' cases," explains Dr. Ken Zaslav, President of the International Cartilage Repair Society (ICRS) and a member of CartiHeal's Clinical Advisory Board. "Based on the robust clinical data of the Agili-C™ implant, FDA has allowed for the first time, treatment indications ranging from single focal defects to multiple defects in osteoarthritis of the knee, which is what us surgeons see on a daily basis. Moreover, this exciting study will compare two control modes in a single arm: microfracture for the treatment of focal lesions and debridement for patients with osteoarthritis." "Over the last few years we've conducted a series of clinical studies in leading centers to learn which kind of patients can benefit from the Agili-C™ implant," says Nir Altschuler, CartiHeal's founder and CEO. "Together with our Clinical Advisory Board we designed a study that targets a large patient population who can potentially benefit from this implant. We are very pleased that FDA approved our study design, and believe that the Agili-C™ implant will prove to be an ideal treatment for a variety of cartilage lesions in patients who wish to return to a painless and active lifestyle, and currently don't have good alternatives." CartiHeal, a privately-held medical device company headquartered in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. Backed by extensive pre-clinical and clinical data, its flagship product Agili-C™, an aragonite-based biodegradable scaffold, has been shown to promote restoration of hyaline cartilage and remodeling of its underlying subchondral bone through a natural process, without the use of cells or growth factors. Clinical results in the knee, ankle and big toe demonstrated the potential of significant improvement in pain reduction, as well as reduction in related symptoms - through a simple, single-step implantation procedure. In the United States, the Agili-C is an investigational device that is limited to use in the IDE study.  It is not available for sale.


News Article | December 7, 2016
Site: globenewswire.com

PORTLAND, Ore., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Stanley Myers, MD, urologist at Northwest Urology, has partnered with HIFU Prostate Services, LLC (HPS), the leading provider of HIFU technology to urology practices in the United States, to make HIFU for prostate cancer available in Portland, Oregon. Dr. Myers is the leading HIFU physician in the Pacific Northwest and has treated men outside the country with HIFU for nearly six years prior to FDA-clearance of the Sonablate® HIFU technology.  HIFU, which stands for high intensity focused ultrasound, is a non-surgical, radiation-free, outpatient procedure that uses focused sound waves to heat and destroy tissue in the prostate gland. Dr. Myers will offer men with localized prostate cancer HIFU with the Sonablate®, the leading HIFU device for prostate ablation. The FDA cleared the Sonablate® technology for the ablation of prostatic tissue in October 2015. No other HIFU prostate treatment device offers revolutionary features that enhance treatment customization and patient safety. These Sonablate features include software that monitors changes in tissue, can locate and spare nerves responsible for preserving potency and incorporates MRI images into live ultrasound images. Dr. Myers is a certified diplomat of the American Board of Urology who was initially certified in 1999 and recertified in 2006 and 2016. He served as president of the Oregon Urological Society (OUS) from 2012 to 2014 and currently serves on the OUS board as past president. “I am very excited to be able to offer HIFU right here in the Pacific Northwest. This will give patients a minimally invasive treatment option for prostate cancer,” said Dr. Myers. "It has been my pleasure to work with Dr. Stan Myers over the last four years in the development of HIFU for use in the Pacific Northwest. Dr. Myers is a very talented surgeon and HIFU practitioner; his establishing this HIFU center will greatly benefit the region," said Michael Lazar, MD, medical director of HIFU Prostate Services. John Linn, chief executive officer of HIFU Prostate Services said, “We only work with the most experienced urologists who are committed to adding HIFU to the list of options that they offer their patients for localized prostate cancer. Dr. Myers is on the forefront of prostate cancer care and we are excited to work with him and his team.” About HIFU Prostate Services, LLC HIFU Prostate Services (HPS) was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate® HIFU. The company is headquartered in Charlotte, NC. Learn more at http://www.hifuprostateservices.com. ­About Northwest Urology Northwest Urology is dedicated to providing the highest quality urologic care to our patients. Our experienced team of physicians are leaders in HIFU, laparoscopic and robotic surgery, and specialize in the full spectrum of urologic services, from general adult urology, to oncologic urology, to pediatric urology. For more than 40 years, Northwest Urology has been providing the Portland area with the highest standard of adult urological care from simple to complex. We have built on a history of regional leadership and innovation, gaining the reputation of being the place to turn to for the difficult or unusual cases. Learn more at http://nwurology.com.


News Article | December 7, 2016
Site: globenewswire.com

PORTLAND, Ore., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Stanley Myers, MD, urologist at Northwest Urology, has partnered with HIFU Prostate Services, LLC (HPS), the leading provider of HIFU technology to urology practices in the United States, to make HIFU for prostate cancer available in Portland, Oregon. Dr. Myers is the leading HIFU physician in the Pacific Northwest and has treated men outside the country with HIFU for nearly six years prior to FDA-clearance of the Sonablate® HIFU technology.  HIFU, which stands for high intensity focused ultrasound, is a non-surgical, radiation-free, outpatient procedure that uses focused sound waves to heat and destroy tissue in the prostate gland. Dr. Myers will offer men with localized prostate cancer HIFU with the Sonablate®, the leading HIFU device for prostate ablation. The FDA cleared the Sonablate® technology for the ablation of prostatic tissue in October 2015. No other HIFU prostate treatment device offers revolutionary features that enhance treatment customization and patient safety. These Sonablate features include software that monitors changes in tissue, can locate and spare nerves responsible for preserving potency and incorporates MRI images into live ultrasound images. Dr. Myers is a certified diplomat of the American Board of Urology who was initially certified in 1999 and recertified in 2006 and 2016. He served as president of the Oregon Urological Society (OUS) from 2012 to 2014 and currently serves on the OUS board as past president. “I am very excited to be able to offer HIFU right here in the Pacific Northwest. This will give patients a minimally invasive treatment option for prostate cancer,” said Dr. Myers. "It has been my pleasure to work with Dr. Stan Myers over the last four years in the development of HIFU for use in the Pacific Northwest. Dr. Myers is a very talented surgeon and HIFU practitioner; his establishing this HIFU center will greatly benefit the region," said Michael Lazar, MD, medical director of HIFU Prostate Services. John Linn, chief executive officer of HIFU Prostate Services said, “We only work with the most experienced urologists who are committed to adding HIFU to the list of options that they offer their patients for localized prostate cancer. Dr. Myers is on the forefront of prostate cancer care and we are excited to work with him and his team.” About HIFU Prostate Services, LLC HIFU Prostate Services (HPS) was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate® HIFU. The company is headquartered in Charlotte, NC. Learn more at http://www.hifuprostateservices.com. ­About Northwest Urology Northwest Urology is dedicated to providing the highest quality urologic care to our patients. Our experienced team of physicians are leaders in HIFU, laparoscopic and robotic surgery, and specialize in the full spectrum of urologic services, from general adult urology, to oncologic urology, to pediatric urology. For more than 40 years, Northwest Urology has been providing the Portland area with the highest standard of adult urological care from simple to complex. We have built on a history of regional leadership and innovation, gaining the reputation of being the place to turn to for the difficult or unusual cases. Learn more at http://nwurology.com.


News Article | November 22, 2016
Site: www.newsmaker.com.au

Future Market Insights delivers key insights on the global teleradiology services market in a new publication titled “Teleradiology Services Market: Global Industry Analysis and Opportunity Assessment, 2016–2026”. Teleradiology is the practice of interpretation and analysis of medical images by a radiologist who is not present at the site where the images are generated. This service is utilised by hospitals, emergency care centres, telemedicine companies, and other clinics. Teleradiology services enable radiologists to use online services in order to improve patient care and treatment without the need to be physically present on site. In terms of revenue, the global teleradiology services market is projected to register a healthy CAGR of 21.0% over the forecast period (2016 – 2026) and increase 6.7x in terms of revenue between 2016 and 2026. The global teleradiology services market is anticipated to project exponential growth over the next 10 years owing to increasing incidences of chronic diseases such as cancer, tumours, and orthopaedic diseases; increasing geriatric population; and excessive hospitalisations and increasing admittance in ambulatory surgical centres and clinics. Increasing consumer awareness regarding teleradiology and easy accessibility to the technology is another key factor likely to drive the global demand for teleradiology services. However, high cost of technology and services, image transmission issues, dearth of trained radiologists and technicians, and a low awareness in emerging economies is likely to pose major challenges for the growth of the global teleradiology services market. Ongoing trends for teleradiology services driving the global market include service offerings with the latest IT infrastructure including artificial intelligence and algorithms, cloud with low maintenance, and image backup storage. The global teleradiology services market is segmented on the basis of Process Type (Certified Reporting Services Process, Preliminary Reporting); Service Type (Emergency Nighthawk, Day Time Coverage, Subspecialty Reading, Second Opinion, Clinical Trails); Modality (X-Ray Scans, Computerised Tomography (CT) Scans, MRI Scans, Ultrasound Scans, Nuclear Scans, Cardiac Echo, Mammography, Electromammography); and End User (Hospital Pharmacies, Clinics, Ambulatory Surgical Centres, Radiology Centres). The global teleradiology services market is segmented on the basis of region into U.S. and OUS (International) (Latin America, EU5, Rest of Europe, Japan, Asia Pacific Excluding Japan, Rest of the World). The U.S. regional market dominated the global teleradiology services market in revenue terms in 2015 and is projected to account for 41.2% market value share by 2026 end. The EU5 region is expected to be the second most lucrative segment in the global teleradiology services market with a market attractiveness index of 1.3 during the forecast period. The report profiles some of the leading players operating in the global teleradiology services market. Top companies featured in the report include Teleradiology Solutions, Argus Radiology, SRL Diagnostics, USARAD Holdings Inc., Vital Radiology Services, Teleradiology Providers, Telemedicine Clinic, TeleDiagnosys Services Pvt. Ltd, Imaging Advantage, Foundation Radiology Group, Direct Radiology, Imaging On Call LLC, ONRAD Inc., Rays (Envision Healthcare Company), StatRad LLC, ARIS Radiology, NightShift Radiology, Mednax Inc., Alta Vista TeleRadiology, and Quality Nighthawk. These established players are focussed on strategic moves such as new product launches, increasing their distribution channels, and getting into partnerships and agreements with hospitals and specialty clinics to increase the brand awareness of their product.

Loading OUS collaborators
Loading OUS collaborators